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Abstract: This study concerns the encapsulation and controlled release of both hydrophobic 
and hydrophilic medications with one polymer, which are delivered together as a combined 
therapy to treat diseased tissue. To test our hypothesis that the novel PEG-graft-PLA (PEG, 
polyethylene glycol; PLA, polylactic acid) can deliver both the hydrophobic and hydrophilic 
medications on account of its amphiphility, charge, and graft structure, PEG-graft-PLA 
(molecular weight of PEG = 1900) with very low critical micelle concentration was synthe-
sized. One hydrophilic (insulin) and one hydrophobic (naproxen) model medication were 
loaded in separately during its self-assembly in aqueous solution. The resulting nanoparticles 
(NPs) were narrowly distributed and spherical, with average particle size around 200 nm, zeta 
potential −10 mV , and encapsulation efficiency 50%. The NPs realized controlled release of 
insulin and naproxen for over 24 and 160 hours, respectively. Specifically, the bioactivity of the 
insulin released from the NPs was maintained. Owing to encapsulation, both for hydrophobic 
and hydrophilic medicines, and NPs obtained with similar size and zeta potential, as well as 
maintenance of bioactivity of loaded protein, we expect the applications of PEG-graft-PLA 
NPs in combination therapy.
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Introduction
Many studies have reported that, in many diseases, combination therapy is more 
  effective than monotherapy.1–5 Although combination therapy is costlier than mono-
therapy in the short term, it offers significant savings in terms of lower treatment-failure 
rate, lower case-fatality ratios, slower development of resistance, and, consequently, 
is less expensive for the development of new drugs. In combination therapy, various 
medications, irrespective of their hydrophobic or hydrophilic nature, have been used.1–5 
In particular, proteins, one of the most effective and fastest growing group of medicines 
for the treatment of nearly 150 diseases, including various severe chronic conditions 
such as cancer, diabetes, hepatitis, leukemia, and rheumatoid arthritis, have shown 
prominent effects.6 However, to date, very few studies have reported the delivery of 
both hydrophobic and hydrophilic medications with one biomaterial, even though 
many single-drug delivery studies have been conducted. Moreover, several problems 
still exist in protein-delivery vehicles, especially due to the denaturation of entrapped 
proteins.7–10 We aimed at developing a system with the capability of encapsulation and 
controlled release of both hydrophobic and hydrophilic medications, especially proteins, International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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and delivering them to the same diseased tissue to realize 
combination therapy. In this study, we focused on carrying 
the hydrophobic and hydrophilic drugs separately.
Polylactic acid (PLA), a known US Food and Drug 
Administration-approved biodegradable polymer for bio-
medical applications,11 has been studied as a drug carrier in 
particle form since 1970.12 However, various drawbacks have 
limited its further application. First, the emulsion method has 
to be used in particle preparation due to the hydrophobicity 
of PLA, where a relatively large amount of organic solvent 
(eg, chloroform, dichloromethane) and surfactant are added. 
Even though the organic solvent is removed afterwards, the 
residual solvent and surfactant may have harmful or cyto-
toxic effects. Second, the particle size prepared by emul-
sion is generally in the micrometer range, which limits the 
encapsulation efficiency and application of PLA particles 
compared with nanoparticles (NPs). Last, PLA particles are 
easily captured by the reticulo-endothelial system13 in vivo 
and eliminated from the body, which in turn limits the use 
ratio of loaded medicine.
To overcome these shortcomings, amphiphilic polymers 
of polyethylene glycol (PEG)–block-PLA, such as diblock 
polymer of PLA-PEG and triblock polymer of PEG-PLA-
PEG, have been synthesized and applied in the encapsulation 
of medications of small molecular weight (Mw), including 
paclitaxel,14 papaverine,15 sulindac, and tetracaine.16 PEG-
block-PLA is a surfactant polymer that can self-assemble into 
nanomicelles and entrap medicines simultaneously, which 
simplifies particle preparation and avoids or minimizes the 
use of the surfactant and organic solvent. Moreover, nanoscale 
vehicles improve the loading rate of medicine compared with 
microscale formulations. The introduction of PEG block also 
suppresses cellular and protein adsorption, thus increasing 
the circulation time of PEG-block-PLA micelles in vivo 
and the effectiveness of the medicine.17 However, although 
PEG-block-PLA improves PLA in many ways, only small 
hydrophobic medications have been encapsulated in them.15–19 
Furthermore, to obtain stable nanomicelles, PEG with a 
molecular weight (Mw) >4000 Da is usually used in the PEG-
block-PLA, which might not be degraded in the body.20 In 
our previous study, a PEG-graft-PLA with PEG of lower Mw 
(600 Da) self-assembled into NPs in water and showed good 
protein resistance and cellular compatibility in vitro.21
In the current study, we hypothesized that PEG-graft-PLA 
could realize the delivery of both hydrophobic and hydro-
philic medications via self-assembly in aqueous medium 
and form NPs with increased circulation time compared 
with   particles of PLA alone, on account of its amiphiphility, 
charge, and graft structure. To test our hypothesis, PEG-graft-
PLA with PEG of Mw 1900 Da was synthesized, followed 
by the critical micelle concentration (CMC) test. One protein 
and one small hydrophobic model medication, insulin and 
naproxen, respectively, were chosen to be loaded. Insulin, a 
peptide hormone composed of 51 amino acids with Mw of 
5808 Da and isoelectric point of 5.3, was chosen to explore 
the possibility of PEG-graft-PLA to encapsulate protein 
medications and keep their bioactivity during entrapment 
and release. Naproxen, a nonsteroidal anti-inflammatory drug 
with a carboxyl group and Mw of 230 Da, was chosen to 
study the capability of PEG-graft-PLA to encapsulate small 
hydrophobic medications and compare the effect with PEG-
block-PLA. The NPs encapsulated with or without (nude 
NPs) insulin or naproxen were prepared and characterized. 
The stability of the NPs under dilution or pH change as well as 
the controlled release of medications was studied in vitro.
Methods
synthesis of Peg-graft-PLA
The PEG-graft-PLA was synthesized as described   previously.21 
Briefly, 20 and 5 mL of tetrahydrofuran (THF) were used to 
dissolve 6.12 g of O,O´-Bis-(2-aminopropyl) polypropylene 
glycol-block-polyethylene oxide-block-polypropylene glycol 
(H2N-PEG-NH2, Mw 1900 Da, Sigma, St Louis, MO) and 
10.00 g of 10% maleic anhydride graft PLA (MPLA), pre-
pared in our lab,22 respectively. To MPLA, H2N-PEG-NH2 
was added dropwise at 50–55°C, followed by 1 more hour 
of stirring. The resulting product was purified by precipita-
tion in 160 mL distilled water and dissolution in 20 mL THF 
three times before being vacuum-dried at room temperature 
to a stable weight. A white and nontransparent solid (that is, 
PEG-graft-PLA), soluble in acetone, chloroform, dimeth-
ylformamide (DMF), and dimethyl sulfoxide (DMSO) was 
yielded. A higher Mw PEG (Mw = 1900) was used in this 
study to realize the encapsulation of both the hydrophobic 
and hydrophilic materials.
cMc tests
To evaluate the surfactivity and the possibility of encap-
sulation, CMC of PEG-graft-PLA was determined using 
the established fluorescence method, with pyrene (Sigma, 
St Louis, MO) as extrinsic probe.23 Serial solutions with fixed 
pyrene concentration of 6.0 × 10–7 M and various concentra-
tions of PEG-graft-PLA between 1.08 × 10–6 and 2.16 × 10–2 
mg/mL were prepared. The excitation intensity of pyrene 
at 329 and 327 nm was obtained (PerkinElmer LS-50B, 
Waltham, MA) according to the scanning excitation spectrum International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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between 321 and 340 nm by fixing the emission spectrum at 
394 nm and the excitation and emission bandwidth at 2.5 nm. 
The CMC was determined by taking the midpoint in the plot 
of the intensity ratio of 329/327 to the logarithm concentra-
tion of PEG-graft-PLA.
Preparation of nude and insulin  
or naproxen-loaded NPs
Procine insulin (Wanbang Biopharma, Jiangsu, China) was 
loaded into PEG-graft-PLA according to the following proce-
dure: 10 mg PEG-graft-PLA dissolved in 1 mL organic solvent 
was dropped into 2 mg insulin solution, obtained by dissolu-
tion in 10 mL of 0.01 N HCl and pH adjusted to 5.3 with 2 N 
NaOH under constant stirring. Naproxen (Hengshuo Chemical 
Co Ltd, Hubei, China) was entrapped by co-dissolving 0.8 mg 
naproxen and 10 mg PEG-graft-PLA in 1 mL organic solvent 
and dropping into 10 mL distilled water under stirring (0.8 mg 
naproxen was supersaturated in 10 mL distilled water). A dif-
ferent organic solvent that can easily mix with water such as 
acetone, THF, DMF, or DMSO could be used in this prepara-
tion. After evaporation (for acetone or THF) or dialysis (for 
DMF or DMSO), to remove organic solvent, NPs encapsulated 
with insulin or naproxen were obtained. The main difference in 
using these solvents was the stability of the obtained NPs. The 
NPs prepared with THF were not as stable as those prepared 
with acetone, DMF, and DMSO. We applied the water solu-
tion of pH 5.3 (for insulin) and distilled water (for naproxen) 
during the entrapment to get lower solubility of the medicine 
in the solution and possible higher loading rate in the NPs. 
The nude PEG-graft-PLA NPs were prepared by dissolving 
10 mg PEG-graft-PLA in 1 mL organic solvent and dropping 
into 10 mL phosphate buffered saline (PBS) under stirring 
before removal of the organic solvent.
NP characterization
The morphology of the nude NPs and the insulin- or naproxen-
loaded NPs was observed by a Philips Tecnai 10 transmission 
electron microscope (Philips, Eindhoven, The Netherlands) 
under 80 kV after staining with 2% sodium phosphotungstate 
for 3 minutes. Average size and zeta potential of the NP 
solution were tested at room temperature by a dynamic light 
scattering (DLS) instrument (Zetasizer Nano S90; Malvern 
Instruments, Worcestershire, UK) using argon ion laser.
NP stability tests
Since NPs are diluted or encounter an acidic or basic environ-
ment besides the neutral conditions in the body, we studied the 
stability of various NPs under dilution (in   aqueous   solutions 
with PBS) or pH change (acidic and basic   conditions). The 
stability of the NPs was also delineated as the average par-
ticle size and zeta potential change before and after dilution 
(10 or 100 times) or pH change (2.0 or 10.5, adjusted with 
0.1 N HCl or NaOH, respectively).
Protein adsorption on the surface of NPs
The protein adsorption on the surface of the NPs was 
used to evaluate its possible circulation time in vivo.21 
The fluorospectrophotometer was used with fluorescein 
  5-isothiocyanate conjugated bovine serum albumin (FITC-
BSA) as model protein based on the fact that albumin is the 
dominant protein in human plasma when adsorbed on PLA.24 
A 5-mL original NP solution was mixed with 5 mL FITC-
BSA water solution (0.04 mg/mL) and incubated at 37°C 
for 40 minutes with stirring before NPs were collected by 
repetitive high-speed centrifuge (Ultra Centrifuge, Beckman 
Coulter, Inc, Brea, CA) at 18,000 rpm for 10 minutes and 
washed with Millipore water. The FITC-BSA-incubated NPs 
were vacuum-dried for 24 hours and dissolved with 3 mL 
DMF. The fluorescent emission of the DMF solution was 
tested with [θ] spectrofluorometer (PerkinElmer LS-50B, 
Maltham, MA) at 510 nm with 490 nm excitation. PLA 
particles prepared by dropping PLA solution in THF to 1% 
gelatin solution in water were used as control. The particle 
size was recorded before adsorption measurement. The ratio 
of FITC-BSA adsorbed on the particles of PEG-graft-PLA 
and PLA was calculated according to their particle size (D) 
and fluorescent emission (E) values as below:
 
% Ratio of FITC-BSA adsorption on
the particles of PEG-graft t-PLA and PLA
DE
DE
PEG-graft-PLAP EG-graft-PLA
PLAP LA
=
×
×
×100%
 
(1)
The encapsulation efficiency and in vitro 
release of insulin and naproxen
The encapsulation efficiency (EE) of insulin in the NPs was 
tested by centrifuging the loaded NPs at 16,000 rpm, 4°C 
for 20 minutes, collecting the supernatant, which contained 
the unencapsulated insulin, and measuring its concentration 
at 595 nm (PerkinElmer LS-50B) after reaction with Coo-
massie brilliant blue for 10 minutes. The EE was calculated 
according to the equation:
(the original insulin added in the NP  
preparation – the insulin in supernatant)/the  
  original insulin added in the NP preparation
  (2)International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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The cumulative release of insulin was tested at 37°C 
and 150 rpm in 30 mL of NP solution, prepared with 5 mL 
original NP solution (without removing the unencapsulated 
insulin) plus 25 mL 0.01 M PBS. At various timepoints, 1 mL 
solution was taken out, centrifuged at 16,000 rpm to collect 
supernatant, and tested for insulin concentration (Coomassie 
brilliant blue coloration method) and bioactivity (porcine 
insulin enzyme-linked immunosorbent assay [ELISA] kit, 
R & D Systems, Inc, Minneapolis, MN). The cumulative 
release of insulin was expressed as the percentage change 
of insulin amount compared with total entrapped insulin 
(tested with Coomassie brilliant blue coloration and ELISA 
method) in bath solution over time. In parallel, the bioactivity 
of 0.08 mg/mL insulin water solution (same concentration 
as the unencapsulated insulin in the NP solution) was tested 
with ELISA as a control. The EE of naproxen was tested 
by centrifuging the NPs at 3000 rpm to collect the unen-
capsulated and insoluble naproxen, followed by dissolving 
the precipitate with DMF and testing the concentration of 
naproxen in DMF at 331 nm. Our preliminary studies have 
shown that the insoluble naproxen in water solution could 
be removed by centrifugation at <3000 rpm. The EE was 
calculated by:
(the original naproxen added in the NP  
preparation – the naproxen in the precipitate – the 
naproxen solubility in water)/the  
  original naproxen added in the NP preparation
 
(3)
The cumulative release of naproxen was tested with the 
dialysis method at 37°C and 150 rpm. A 5-mL NP solution 
in which the unencapsulated and insoluble naproxen had 
been removed via centrifuge at 3000 rpm was put into a 
dialysis membrane (cut off Mw = 8000 Da) followed by the 
addition of 45 mL PBS as dialysis solution. A 1-mL dialysis 
solution was sampled, and an equal amount of fresh PBS 
was added at various timepoints. The naproxen concentra-
tion was directly tested at 331 nm where the PEG-graft-PLA 
had no absorbance. The cumulative release of naproxen was 
expressed as the percentage change of naproxen amount 
in dialysis solution compared with the total entrapped 
naproxen over time. Each test was replicated three times.
Results
Low cMc of Peg-graft-PLA in water
The CMC of PEG-graft-PLA in water was 2.0 × 10–3 mg/mL, 
as shown in Figures 1A and 1B, which was comparable 
to PEG-block-PLA16 and one order lower than Tween 80 
(ie, 1.4 × 10–2 mg/mL), one of the most commonly used 
surfactants in particle preparation. The result showed its 
good surfactivity.
Morphology and nanostructure of NPs
The nude NPs as well as NPs loaded with insulin or naproxen 
were found to be spherical in structure, as shown in Figure 2. 
The representative average particle size was 114.7 nm (for 
nude NPs), 173 nm (for insulin), and 278.4 nm (for naproxen). 
The size distribution of NPs was very low (PDI [polydis-
persity index] was <0.3). The representative average zeta 
potential was −27.84 mV for nude NPs, −45.21 mV for insu-
lin, and −14.42 mV for naproxen (Figure 3, original NPs).
stability of NPs under dilution and ph 
change
The NPs loaded with or without insulin or naproxen were 
relatively stable after 10× and 100× dilution as well as pH 
change to 10.5 (Figure 3), while the NPs remained stable 
during the acidification, until the pH jumped to 2.0 when 
they aggregated immediately (Figure 3). The results sug-
gested the buffering effect of PEG-graft-PLA in aqueous 
solution.
BsA-resistant property of NPs
There was 95.1% less FITC-BSA adsorbed on nude NPs 
of PEG-graft-PLA than on nude PLA particles. The results 
indicated the BSA-resistant property of PEG-graft-PLA NPs 
and possible longer circulation in the bloodstream.21
encapsulation and in vitro release  
of insulin and naproxen
The encapsulation efficiency of insulin and naproxen in NPs 
of PEG-graft-PLA was >60% and 50%, respectively. About 
80% of the loaded insulin and naproxen were released within 
24 hours for insulin (tested with Coomassie brilliant blue 
coloration method) and 160 hours for naproxen (Figure 4). 
The burst release of insulin and naproxen within 2 hours 
was about 27% and 32%, respectively, which may relate to 
the surface adsorption of medicine on NPs (Figure 4). We 
found a slight drop at 4 hours compared with 2 hours in 
insulin release curve which may be due to the re-adsorption 
of burst-released insulin onto the NPs while there was less 
release, or no release at all, of inner insulin from the NPs.
We found that the bioactivity of insulin in PBS solution 
decreased with time (half-life was about 8 hours), while 
the bioactivity in NP solution appeared to increase a little 
and then drop (half-life was about 24 hours) (Figure 5A). International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure 1 cMc determination of Peg-graft-PLA. (A) excitation spectra of pyrene from 321 to 340 nm as a function of Peg-graft-PLA concentration in water. (B) Intensity ratio 
(329/327) of pyrene versus logarithm concentration of Peg-graft-PLA. The cMc was determined by taking the midpoint in the plot of (B), which was 2.0 × 10–3 mg/mL.
Abbreviations: cMc, critical micelle concentration; Peg, polyethylene glycol; PLA, polylactic acid.
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Figure 2 spherical morphology of nude NPs (A) and NPs encapsulated with insulin (B) or naproxen (C) observed via transmission electron microscopy. 
Note: scale bar: 200 nm.
Abbreviation: NP, nanoparticle.
The increase within 2 hours was from the burst release, which 
showed that the burst-released insulin was bioactive. The 
bioactivity of insulin released from the NPs, calculated by 
the bioactivity in NPs solution minus the bioactivity in PBS, 
increased with time (Figure 5B), from which we inferred 
that the bioactive insulin was released from the NPs for over 
24 hours (Figure 5B).
Discussion
Although a number of studies have reported the delivery 
of single medicines, very few studies have shown the 
development of self-assembled NPs with one polymer in 
aqueous solution which could carry both the hydrophobic 
and hydrophilic medications, particularly the large proteins 
with sustained bioactivity. PEG-graft-PLA is a kind of 
amphiphilic polymer with graft PEG structure that is flexible 
in solution. It contains free amino and carboxyl groups that 
ionize and interact in water. These features enable it to self-
assemble and entrap chemicals via hydrophilic/hydrophobic 
and   electrostatic interaction. Our results demonstrated the 
good surfactivity of PEG-graft-PLA and its capability to 
load   insulin and naproxen during self-assembly in aqueous 
medium to receive NPs and realize controlled release. In fact, 
we also found that the PEG-graft-PLA can encapsulate dur-
ing the self-assembly and controlled release of many other 
hydrophobic and hydrophilic chemicals, including sodium 
fluorescein and fluorescein isothiocyanate in aqueous solution 
(data not shown). The potential encapsulation of PEG-graft-
PLA for the hydrophobic and hydrophilic materials implied 
that PEG-graft-PLA formed a hydrophobic and hydrophilic 
inner-layer with a hydrophilic out-layer during self-assembly 
in aqueous solution, as shown in Figure 6. Thus, we expected 
these NPs loaded with different drugs would arrive at the 
same diseased tissue and realize the combination therapy 
according to their similar chemical character, particle size, 
and zeta potential. Of course, it needs further study.
We obtained the spherical, narrowly distributed, and 
negatively charged NPs loaded with insulin or naproxen 
by way of self-assembly, with no surfactant and much less 
of the organic solvent compared with when PLA particles International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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were used. So we would expect the PEG-graft-PLA NPs to 
be more   biocompatible than the PLA particles. The NPs have 
particle size around 200 nm, zeta potential >−10 mV , and 
encapsulation efficiency >50%. The first order kinetics with 
>80% release of insulin and naproxen was realized within 
24 hours and 160 hours, respectively, in vitro (Figures 4A 
and 4B). In addition, the NPs of PEG-graft-PLA showed 
BSA-resistant properties compared with PLA particles. In 
fact, we have previously demonstrated the BSA resistance of 
PEG-graft-PLA film compared with PLA film.21 The good 
protein-resistant property of PEG-graft-PLA NPs may ensure 
its long circulation in the bloodstream.21 The stability study 
disclosed that the NPs could be stable after administration in 
the body and diluted by blood or encountered with neutral 
(ie, pH 7.0) and basic tissue fluid, eg, intestinal fluid, but may 
aggregate in acidic fluid, especially in the gastric fluid. There-
fore, it is reasonable to expect that the NPs of PEG-graft-PLA 
could be acidic-environment targeting and used for targeted 
and controlled drug delivery for stomach diseases and many 
tumors that have lower pH than normal tissue. We also found 
the original NP solution loaded with insulin or naproxen was 
stable at room temperature for at least 1 week.
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Figure 4 Typical in vitro insulin (A) (tested with coomassie brilliant blue coloration method) and naproxen (B) release profile from nanoparticles of PEG-graft-PLA.
Abbreviations: Peg, polyethylene glycol; PLA, polylactic acid.
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Many studies have used chitosan with or without other 
polymers, such as Eudragit L 100-55,25 arabic gum,26 
dextran sulfate,27 and alginate28 to prepare NPs with encap-
sulated insulin owing to its positive charge, and potential 
mucoadhesive and membrane permeable properties. They 
achieved particle size of 200–750 nm, zeta potential of −5 
to −15 mV , encapsulation efficiency of 40%–85%, entrap-
ment of 3.38%,25 and controlled release of <30 minutes28 
and 6 hours.27 A crosslinked dextran,29 insulin-sodium 
oleate complex-loaded poly(lactide-co-glycolide),30 and 
polyelectrolyte31 NPs got an encapsulation efficiency of 
45%–91.2%, particle size of 100–250 nm, and controlled 
release with 75%–95% entrapped insulin within 48 hours29 
and 6 hours.31 We have acheived particle size and encapsu-
lation efficiency comparable to the NPs obtained in these 
studies, but prominent higher zeta potential value even after 
dilution or pH change to basic conditions (Figure 3). The 
high zeta potential hints at the stability of NPs under stor-
age.32 Moreover, the high negative charge of insulin-loaded 
PEG-graft-PLA NPs favors their long stay in the bloodstream 
because the surface of blood cells and endothelia are nega-
tively charged.33 Sarmento et al also tested the bioactivity 
and concentration of insulin released from polysaccharide 
NPs with ELISA and the Bradford method and found that 
the relative bioactivity, a comparison of bioactivity with the 
concentration, remained for up to 24 hours.34 We found the 
relative concentration of both the pure insulin in PBS and 
insulin released from NPs decreased with time in 24 hours, 
even though the latter decreased slower than the former (data 
not shown). In addition, the storage of raw insulin influenced 
the loading and release results due to its aggregation. The 
results we report here were from fresh insulin. Our study 
demonstrated that insulin released from NPs retained its 
bioactivity, which makes PEG-graft-PLA NPs more attrac-
tive for other therapeutic protein delivery, although more 
in vivo studies are needed.
Poly(D,L-lactide-co-glycolide),35 poly-caprolactone,36 
liposomes,37 and aspartate-based dendrimers38 have been 
0
2000
4000
6000
8000
10000
12000
14000
16000
05 10 15
Time (h)
I
n
s
u
l
i
n
 
b
i
o
a
c
t
i
v
i
t
y
 
(
m
U
/
L
)
0
2000
−2000
4000
6000
8000
10000
I
n
s
u
l
i
n
 
b
i
o
a
c
t
i
v
i
t
y
 
(
m
U
/
L
)
20
Insulin in NPs/PBS solution
Insulin in PBS solution
25 05 10 15
Time (h)
20 25
AB
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Abbreviations: NP, nanoparticle; PBs, phosphate buffered saline.
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Figure 6 The formation of Peg-graft-PLA NPs when loaded with insulin (A) and naproxen (B).
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used for naproxen delivery, with particle size ranging from 
100 to 723 nm, a loading ratio of up to 98%,35 a sustained 
1-month in vivo release,36 and an increased solubility of up 
to two-fold at pH 6 and 7.38 PEG-block-PLA used for small 
hydrophobic-medicine delivery gave particle sizes as small as 
45 nm,16 loading rate up to 25%,16 controlled release of up to 
450 hours,17 and 5000-fold increased solubility.16 We obtained 
effects comparable with the published naproxen delivery 
systems and the PEG-block-PLA for small hydrophobic 
medications.
In conclusion, we have developed PEG-graft-PLA NPs 
with the potential for encapsulation and controlled release of 
both hydrophobic and hydrophilic medications. Specifically, 
they retained the bioactivity of the entrapped protein.
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